Jump to content

Vitamin K: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
m Reverted edits by Bobisawesome123 (talk) to last revision by ClueBot NG (HG)
Tag: gettingstarted edit
Line 34: Line 34:
== Discovery of vitamin K<sub>1</sub> ==
== Discovery of vitamin K<sub>1</sub> ==


Vitamin k is something that varan likes to suck on when he is in the shower
Vitamin K<sub>1</sub> was identified in 1929 by [[Denmark|Danish]] scientist [[Henrik Dam]] when he investigated the role of [[cholesterol]] by feeding chickens a cholesterol-depleted diet.<ref name="Dam">{{cite journal|last=Dam|first=H.|year=1935|title=The Antihæmorrhagic Vitamin of the Chick.: Occurrence And Chemical Nature|journal=Nature|volume=135|issue=3417|pages=652–653|doi=10.1038/135652b0 }}</ref> After several weeks, the animals developed haemorrhages and started bleeding. These defects could not be restored by adding purified cholesterol to the diet. It appeared that—together with the cholesterol—a second compound had been extracted from the food, and this compound was called the coagulation vitamin. The new vitamin received the letter '''K''' because the initial discoveries were reported in a German journal, in which it was designated as ''Koagulationsvitamin.''


==Conversion of vitamin K<sub>1</sub> to vitamin K<sub>2</sub> in animals==
==Conversion of vitamin K<sub>1</sub> to vitamin K<sub>2</sub> in animals==

Revision as of 14:12, 13 April 2014

"Vitamin K" is also a slang term for ketamine, an unrelated anaesthetic.

Vitamin K
Drug class
Class identifiers
UseVitamin K deficiency
ATC codeB02BA
Biological targetGamma-glutamyl carboxylase
Clinical data
Drugs.comMedical Encyclopedia
External links
MeSHD014812
Legal status
In Wikidata
Vitamin K1 (phylloquinone) - both forms of the vitamin contain a functional naphthoquinone ring and an aliphatic side-chain. Phylloquinone has a phytyl side-chain.
Vitamin K2 (menaquinone). In menaquinone, the side-chain is composed of a varying number of isoprenoid residues. The most common number of these residues is four, since animal enzymes normally produce menaquinone-4 from plant phylloquinone.
A sample of phytomenadione (vitamin K1) for injection, also called phylloquinone.

Vitamin K is a group of structurally similar, fat-soluble vitamins that the human body needs for post-translational modification of certain proteins required for blood coagulation, and in metabolic pathways in bone and other tissue. They are 2-methyl-1,4-naphthoquinone (3-) derivatives. This group of vitamins includes two natural vitamers: vitamin K1 and vitamin K2.[1]

Vitamin K1, also known as phylloquinone, phytomenadione, or phytonadione, is synthesized by plants, and is found in highest amounts in green leafy vegetables because it is directly involved in photosynthesis. It may be thought of as the "plant form" of vitamin K. It is active in animals and may perform the classic functions of vitamin K in animals, including its activity in the production of blood-clotting proteins. Animals may also convert it to vitamin K2.

Vitamin K2, the main storage form in animals, has several subtypes, which differ in isoprenoid chain length. These vitamin K2 homologues are called menaquinones, and are characterized by the number of isoprenoid residues in their side chains. Menaquinones are abbreviated MK-n, where M stands for menaquinone, the K stands for vitamin K, and the n represents the number of isoprenoid side chain residues. For example, menaquinone-4 (abbreviated MK-4) has four isoprene residues in its side chain. Menaquinone-4 (also known as menatetrenone from its four isoprene residues) is the most common type of vitamin K2 in animal products since MK-4 is normally synthesized from vitamin K1 in certain animal tissues (arterial walls, pancreas, and testes) by replacement of the phytyl tail with an unsaturated geranylgeranyl tail containing four isoprene units, thus yielding menaquinone-4. This homolog of vitamin K2 may have enzyme functions that are distinct from those of vitamin K1.

Bacteria in the colon (large intestine) can also convert K1 into vitamin K2. In addition, bacteria typically lengthen the isopreneoid side chain of vitamin K2 to produce a range of vitamin K2 forms, most notably the MK-7 to MK-11 homologues of vitamin K2. All forms of K2 other than MK-4 can only be produced by bacteria, which use these forms in anaerobic respiration. The MK-7 and other bacteria-derived form of vitamin K2 exhibit vitamin K activity in animals, but MK-7's extra utility over MK-4, if any, is unclear and is presently a matter of investigation.

Three synthetic types of vitamin K are known: vitamins K3, K4, and K5. Although the natural K1 and all K2 homologues have proven nontoxic, the synthetic form K3 (menadione) has shown toxicity.[2] K4, and K5 are also non toxic.

Discovery of vitamin K1

Vitamin k is something that varan likes to suck on when he is in the shower

Conversion of vitamin K1 to vitamin K2 in animals

The MK-4 form of vitamin K2 is produced via conversion of vitamin K1 in the testes, pancreas, and arterial walls.[3] While major questions still surround the biochemical pathway for the transformation of vitamin K1 to MK-4, the conversion is not dependent on gut bacteria, as it occurs in germ-free rats[4][5] and in parenterally-administered K1 in rats.[6][7] In fact, tissues that accumulate high amounts of MK-4 have a remarkable capacity to convert up to 90% of the available K1 into MK-4.[8][9] There is evidence that the conversion proceeds by removal of the phytyl tail of K1 to produce menadione as an intermediate, which is then condensed with an activated geranylgeranyl moiety (see also prenylation) to produce vitamin K2 in the MK-4 (menatetrione) form.[10]

Subtypes of vitamin K2

Main article: Vitamin K2

Vitamin K2 (menaquinone) includes several subtypes. The two subtypes most studied are menaquinone-4 (menatetrenone, MK-4) and menaquinone-7 (MK-7).

Menaquinone-7 is different from MK-4 in that it is not produced by human tissue. MK-7 consumption has been shown to reduce the risk of bone fractures and cardiovascular disorders that are crucial health issues worldwide. Recently, leading research teams from Australia, Japan, and Korea are broadening the understanding of MK-7 and its production. It has been reported that MK-7 may be converted from phylloquinone (K1) in the colon by E. coli bacteria.[11] However, bacteria-derived menaquinones (MK-7) appear to contribute minimally to overall vitamin K status.[12][13] MK-4 and MK-7 are both found in the United States in dietary supplements for bone health.

The U.S. Food and Drug Administration (FDA) has not approved any form of vitamin K for the prevention or treatment of osteoporosis; however, MK-4 has been shown to decrease the incidence of fractures up to 87%.[14] MK-4 (45 mg daily) has been approved by the Ministry of Health in Japan since 1995 for the prevention and treatment of osteoporosis.[15]

Vitamin K2 as MK-4, but not as MK-7 (and also not vitamin K1) has also been shown to prevent bone loss and/or fractures in the following circumstances:

Chemical structure

The three synthetic forms of vitamin K are vitamins K3, K4, and K5, which are used in many areas, including the pet food industry (vitamin K3) and to inhibit fungal growth (vitamin K5).[32]

Physiology

Vitamin K1, the precursor of most vitamin K in nature, is a steroisomer of phylloquinone, an important chemical in green plants, where it functions as an electron acceptor in photosystem I during photosynthesis. For this reason, vitamin K1 is found in large quantities in the photosynthetic tissues of plants (green leaves, and dark green leafy vegetables such as romaine lettuce, kale and spinach), but it occurs in far smaller quantities in other plant tissues (roots, fruits, etc.). Iceberg lettuce contains relatively little. The function of phylloquinone in plants appears to have no resemblance to its later metabolic and biochemical function (as "vitamin K") in animals, where it performs a completely different biochemical reaction.

Vitamin K (in animals) is involved in the carboxylation of certain glutamate residues in proteins to form gamma-carboxyglutamate (Gla) residues. The modified residues are often (but not always) situated within specific protein domains called Gla domains. Gla residues are usually involved in binding calcium, and are essential for the biological activity of all known Gla proteins.[33]

At this time, 16 human proteins with Gla domains have been discovered, and they play key roles in the regulation of three physiological processes:

Like other lipid-soluble vitamins (A, D, E), vitamin K is stored in the fat tissue of the human body.

Vitamin K absorption and dietary need

Previous theory held that dietary deficiency is extremely rare unless the intestine (small bowel) was heavily damaged, resulting in malabsorption of the molecule. Another at-risk group for deficiency were those subject to decreased production of K2 by normal intestinal microbiota, as seen in broad spectrum antibiotic use.[41] Taking broad-spectrum antibiotics can reduce vitamin K production in the gut by nearly 74% in people compared with those not taking these antibiotics.[42] Diets low in vitamin K also decrease the body's vitamin K concentration.[43] Those with chronic kidney disease are at risk for vitamin K deficiency, as well as vitamin D deficiency, and particularly those with the apoE4 genotype.[44] Additionally, in the elderly there is a reduction in vitamin K2 production.[45]

Recent research results also demonstrate that the small intestine and large intestine (colon) seem to be inefficient at absorbing vitamin K supplements in rat populations low in Vitamin K.[46][47] These results are reinforced by human cohort studies, where a majority of the subjects showed inadequate vitamin K amounts in the body. This was revealed by the presence of large amounts of incomplete gamma-carboxylated proteins in the blood, an indirect test for vitamin K deficiency.[48][49][50] And in an animal model MK-4 was shown to prevent arterial calcifications, pointing to its potential role in prevention of such calcification.[51] In this study vitamin K1 was also tested, in an attempt to make connections between vitamin K1 intake and calcification reduction. Only vitamin K2 (as MK-4) was found to influence warfarin-induced calcification in this study.

The U.S. Dietary Reference Intake (DRI) for an Adequate Intake (AI) of vitamin K for a 25-year old male is 120 micrograms (μg) per day. The AI for adult women is 90 μg/day, for infants is 10–20 μg/day, and for children and adolescents 15–100 μg/day. To get maximum carboxylation of osteocalcin, one may have to take up to 1000 μg of vitamin K1.[52]

Anticoagulant drug interactions

Phylloquinone (K1)[53][54] or menaquinone (K2) are capable of reversing the anticoagulant activity (incorrectly but colloquially referred to as "blood-thinning action") of the powerful anticoagulant warfarin (tradename Coumadin). Warfarin works by blocking recycling of vitamin K, so that the body and tissues have lower levels of active vitamin K, and thus a deficiency of the active vitamin.

Supplemental vitamin K (for which oral dosing is often more active than injectable dosing in human adults) reverses the vitamin K deficiency caused by warfarin, and therefore modulates or totally reverses the intended anticoagulant action of warfarin and related drugs.[citation needed] Foods containing high amounts of vitamin K (green leafy vegetables) are avoided when taking warfarin .[citation needed] Sometimes small amounts of vitamin K (one milligram per day) are given orally to patients taking Coumadin so that the action of the drug is more predictable. [citation needed] The proper anticoagulant action of the drug is a function of vitamin K intake and drug dose, and (due to differing absorption) must be individualized for each patient.[citation needed] The action of warfarin and vitamin K both require two to five days after dosing to have maximum effect, and neither Coumadin or vitamin K shows much effect in the first 24 hours after they are given.[citation needed]

In two separate studies in the rat model, after long term administration of Coumadin to induce calcification of arteries in the rodents, supplemental vitamin K was found to reverse or prevent some of the arterial calcification attendant on the long-term blockade of vitamin K.[55] A second study found that only vitamin K2 as MK-4, and not vitamin K1 was effective at preventing warfarin-induced arterial calcification in rats, suggesting differing roles for the two forms of the vitamin in some calcium-dependent processes.[56]

The newer anticoagulants dabigatran and rivaroxaban have different mechanisms of action that do not interact with vitamin K, and may be taken with supplemental vitamin K.[57][58]

Food sources

Vitamin K1

Food Serving Size Vitamin K1[59] Microgram (μg) Food Serving Size Vitamin K1[59] Microgram (μg)
Kale, cooked 1/2 cup 531 Parsley, raw 1/4 cup 246
Spinach, cooked 1/2 cup 444 Spinach, raw 1 cup 145
Collards, cooked 1/2 cup 418 Collards, raw 1 cup 184
Swiss chard, cooked 1/2 cup 287 Swiss chard, raw 1 cup 299
Mustard greens, cooked 1/2 cup 210 Mustard greens, raw 1 cup 279
Turnip greens, cooked 1/2 cup 265 Turnip greens, raw 1 cup 138
Broccoli, cooked 1 cup 220 Broccoli, raw 1 cup 89
Brussels sprouts, cooked 1 cup 219 Endive, raw 1 cup 116
Cabbage, cooked 1/2 cup 82 Green leaf lettuce 1 cup 71
Asparagus 4 spears 48 Romaine lettuce, raw 1 cup 57
Table from "Important information to know when you are taking: Warfarin (Coumadin) and Vitamin K", Clinical Center, National Institutes of Health Drug Nutrient Interaction Task Force.[60]

Vitamin K1 is found chiefly in leafy green vegetables such as dandelion greens (which contain 778.4 μg per 100 g, or 741% of the recommended daily amount), spinach, swiss chard, and Brassica (e.g. cabbage, kale, cauliflower, broccoli, lettuce, and brussels sprouts) and often the absorption is greater when accompanied by fats such as butter or oils; some fruits, such as avocado, kiwifruit and grapes, are also high in vitamin K. By way of reference, two tablespoons of parsley contain 153% of the recommended daily amount of vitamin K.[61] Some vegetable oils, notably soybean, contain vitamin K, but at levels that would require relatively large calorific consumption to meet the USDA-recommended levels.[62] Colonic bacteria synthesize a significant portion of humans' vitamin K needs; newborns often receive a vitamin K shot at birth to tide them over until their colons become colonized at five to seven days of age from the consumption of their mother's milk.

Phylloquinone's tight binding to thylakoid membranes in chloroplasts makes it less bioavailable. For example, cooked spinach has a 5% bioavailability of phylloquinone, however, fat added to it increases bioavailability to 13% due to the increased solubility of vitamin K in fat.[63]

Vitamin K2

Main article: Vitamin K2

Food sources of vitamin K2 include fermented or aged cheeses, eggs, meats such as chicken and beef and their fat, livers, and organs, and in fermented vegetables, especially natto, as well as sauerkraut and kefir.[64]

Food 100 grams (3.5 oz) portion Microgram (μg) Proportion of vitamin K2 Food 100 grams (3.5 oz) portion Microgram (μg) Proportion of vitamin K2
Natto, cooked 1,103.4 (90% MK-7, 10% other MK) Chicken Leg 8.5 (100% MK-4)
Goose liver pâté 369.0 (100% MK-4) Ground beef (medium fat) 8.1 (100% MK-4)
Hard cheeses (Dutch Gouda style), raw 76.3 (6% MK-4, 94% other MK) Chicken liver (braised) 6.7 (100% MK-4)
Soft cheeses (French Brie style) 56.5 (6.5 MK-4, 93.5% other MK) Hot dog 5.7 (100% MK-4)
Egg yolk, (Netherlands) 32.1 (98% MK-4, 2% other MK) Bacon 5.6 (100% MK-4)
Goose leg 31.0 (100% MK-4) Calf’s liver (pan-fried) 6.0 (100% MK-4)
Egg yolk (U.S.) 15.5 (100% MK-4) Sauerkraut 4.8 (100% MK-4)
Butter 15.0 (100% MK-4) Whole milk 1.0 (100% MK-4)
Chicken liver (raw) 14.1 (100% MK-4) Salmon (Alaska, Coho, Sockeye, Chum, and King wild (raw)) 0.5 (100% MK-4)
Chicken liver (pan-fried) 12.6 (100% MK-4) Cow’s liver (pan-fried) 0.4 (100% MK-4)
Cheddar cheese (U.S.) 10.2 (6% MK-4, 94% other MK) Egg white 0.4 (100% MK-4)
Meat franks 9.8 (100% MK-4) Skim milk 0.0
Chicken breast 8.9 (100% MK-4)
Table from Rhéaume-Bleue, pp. 66–67.

Vitamin K2 (menaquinone-4) is synthesized by animal tissues and is found in meat, eggs, and dairy products.[65] Menaquinone-7 is synthesized by bacteria during fermentation and is found in fermented soybeans (natto), and in most fermented cheeses.[66] In natto, none of the vitamin K is from menaquinone-4, and in cheese only 2–7% is.[67]

Deficiency

Main article: Vitamin K deficiency

Average diets are usually not lacking in vitamin K, and primary deficiency is rare in healthy adults. Newborn infants are at an increased risk of deficiency. Other populations with an increased prevalence of vitamin K deficiency include those who suffer from liver damage or disease (e.g. alcoholics), cystic fibrosis, or inflammatory bowel diseases, or have recently had abdominal surgeries. Secondary vitamin K deficiency can occur in bulimics, those on stringent diets, and those taking anticoagulants. Other drugs associated with vitamin K deficiency include salicylates, barbiturates, and cefamandole, although the mechanisms are still unknown. Vitamin K1 deficiency can result in coagulopathy, a bleeding disorder.[68] Symptoms of K1 deficiency include anemia, bruising, and bleeding of the gums or nose in both sexes, and heavy menstrual bleeding in women.

Osteoporosis[69][70] and coronary heart disease[71][72] are strongly associated with lower levels of K2 (menaquinone). Vitamin K2 (MK-7) deficiency is also related to severe aortic calcification and all-cause mortality.[73] Menaquinone is not inhibited by salicylates as happens with K1, so menaquinone supplementation can alleviate the chronic vitamin K deficiency caused by long-term aspirin use.[citation needed]

Toxicity

Although allergic reaction from supplementation is possible, no known toxicity is associated with high doses of the phylloquinone (vitamin K1) or menaquinone (vitamin K2) forms of vitamin K, so no tolerable upper intake level (UL) has been set.[74]

Blood clotting (coagulation) studies in humans using 45 mg per day of vitamin K2 (as MK-4)[26] and even up to 135 mg/day (45 mg three times daily) of K2 (as MK-4),[75] showed no increase in blood clot risk. Even doses in rats as high as 250 mg/kg body weight did not alter the tendency for blood-clot formation to occur.[76]

Unlike the safe natural forms of vitamin K1 and vitamin K2 and their various isomers, a synthetic form of vitamin K, vitamin K3 (menadione), is demonstrably toxic. The U.S. FDA has banned this form from over-the-counter sale in the United States because large doses have been shown to cause allergic reactions, hemolytic anemia, and cytotoxicity in liver cells.[2]

Biochemistry

Function in animals

Vitamin K structures. MK-4 and MK-7 are both subtypes of K2.

The function of vitamin K2 in the animal cell is to add a carboxylic acid functional group to a glutamate amino acid residue in a protein, to form a gamma-carboxyglutamate (Gla) residue. This is a somewhat uncommon posttranslational modification of the protein, which is then known as a "Gla protein." The presence of two -COOH (carboxylate) groups on the same carbon in the gamma-carboxyglutamate residue allows it to chelate calcium ion. The binding of calcium ion in this way very often triggers the function or binding of Gla-protein enzymes, such as the so-called vitamin K dependent clotting factors discussed below.

Within the cell, vitamin K undergoes electron reduction to a reduced form called vitamin K hydroquinone by the enzyme vitamin K epoxide reductase (VKOR).[77] Another enzyme then oxidizes vitamin K hydroquinone to allow carboxylation of Glu to Gla; this enzyme is called the gamma-glutamyl carboxylase[78][79] or the vitamin K-dependent carboxylase. The carboxylation reaction only proceeds if the carboxylase enzyme is able to oxidize vitamin K hydroquinone to vitamin K epoxide at the same time. The carboxylation and epoxidation reactions are said to be coupled. Vitamin K epoxide is then reconverted to vitamin K by VKOR. The reduction and subsequent reoxidation of vitamin K coupled with carboxylation of Glu is called the vitamin K cycle.[80] Humans are rarely deficient in vitamin K1 because, in part, vitamin K 1 is continuously recycled in cells.[81]

Warfarin and other 4-hydroxycoumarins block the action of the VKOR.[82] This results in decreased concentrations of vitamin K and vitamin K hydroquinone in the tissues, such that the carboxylation reaction catalyzed by the glutamyl carboxylase is inefficient. This results in the production of clotting factors with inadequate Gla. Without Gla on the amino termini of these factors, they no longer bind stably to the blood vessel endothelium and cannot activate clotting to allow formation of a clot during tissue injury. As it is impossible to predict what dose of warfarin give the desired degree of clotting suppression, warfarin treatment must be carefully monitored to avoid overdose.

Gamma-carboxyglutamate proteins

At present, the following human Gla-containing proteins have been characterized to the level of primary structure: the blood coagulation factors II (prothrombin), VII, IX, and X, the anticoagulant proteins C and S, and the factor X-targeting protein Z. The bone Gla protein osteocalcin, the calcification-inhibiting matrix Gla protein (MGP), the cell growth regulating growth arrest specific gene 6 protein (Gas6), and the four transmembrane Gla proteins (TMGPs), the function of which is at present unknown. Gas6 can function as a growth factor to activate the Axl receptor tyrosine kinase and stimulate cell proliferation or prevent apoptosis in some cells. In all cases in which their function was known, the presence of the Gla residues in these proteins turned out to be essential for functional activity.

Gla proteins are known to occur in a wide variety of vertebrates: mammals, birds, reptiles, and fish. The venom of a number of Australian snakes acts by activating the human blood-clotting system. In some cases, activation is accomplished by snake Gla-containing enzymes that bind to the endothelium of human blood vessels and catalyze the conversion of procoagulant clotting factors into activated ones, leading to unwanted and potentially deadly clotting.

Another interesting class of invertebrate Gla-containing proteins is synthesized by the fish-hunting snail Conus geographus.[83] These snails produce a venom containing hundreds of neuroactive peptides, or conotoxins, which is sufficiently toxic to kill an adult human. Several of the conotoxins contain two to five Gla residues.[84]

Methods of assessment

Vitamin K status can be assessed by:

  • The prothrombin time (PT) test measures the time required for blood to clot. A blood sample is mixed with citric acid and put in a fibrometer; delayed clot formation indicates a deficiency. This test is insensitive to mild deficiency, as the values do not change until the concentration of prothrombin in the blood has declined by at least 50%.[85]
  • Undercarboxylated prothrombin (PIVKA-II), in a study of 53 newborns, found "PT (prothrombin time) is a less sensitive marker than PIVKA II",[86] and as indicated above, PT is unable to detect subclinical deficiencies that can be detected with PIVKA-II testing.
  • Plasma phylloquinone was found to be positively correlated with phylloquinone intake in elderly British women, but not men,[87]

but an article by Schurges et al. reported no correlation between FFQ [further explanation needed] and plasma phylloquinone.[88]

  • Urinary γ-carboxyglutamic acid responds to changes in dietary vitamin K intake. Several days are required before any change can be observed. In a study by Booth et al., increases of phylloquinone intakes from 100 μg to between 377 and 417 μg for five days did not induce a significant change. Response may be age-specific.[89]
  • Undercarboxylated osteocalcin (UcOc) levels have been inversely correlated with stores of vitamin K[90] and bone strength in developing rat tibiae. Another study following 78 postmenopausal Korean women found a supplement regimen of vitamins K and D, and calcium, but not a regimen of vitamin D and calcium, was inversely correlated with reduced UcOc levels.[91]

Function in bacteria

Many bacteria, such as Escherichia coli found in the large intestine, can synthesize vitamin K2 (menaquinone-7 or MK-7, up to MK-11),[92] but not vitamin K1 (phylloquinone). In these bacteria, menaquinone transfers two electrons between two different small molecules, during oxygen-independent metabolic energy production processes (anaerobic respiration).[93] For example, a small molecule with an excess of electrons (also called an electron donor) such as lactate, formate, or NADH, with the help of an enzyme, passes two electrons to a menaquinone. The menaquinone, with the help of another enzyme, then transfers these two electrons to a suitable oxidant, such fumarate or nitrate (also called an electron acceptor). Adding two electrons to fumarate or nitrate converts the molecule to succinate or nitrite + water, respectively.

Some of these reactions generate a cellular energy source, ATP, in a manner similar to eukaryotic cell aerobic respiration, except the final electron acceptor is not molecular oxygen, but fumarate or nitrate. In aerobic respiration, the final oxidant is molecular oxygen (O2), which accepts four electrons from an electron donor such as NADH to be converted to water. E. coli can carry out aerobic respiration and menaquinone-mediated anaerobic respiration.

Vitamin K injection in newborns

The blood clotting factors of newborn babies are roughly 30 to 60% that of adult values; this may be due to the reduced synthesis of precursor proteins and the sterility of their guts. Human milk contains 1–4 μg/L of vitamin K1, while formula-derived milk can contain up to 100 μg/L in supplemented formulas. Vitamin K2 concentrations in human milk appear to be much lower than those of vitamin K1. Occurrence of vitamin K deficiency bleeding in the first week of the infant's life is estimated at 0.25 to 1.7%, with a prevalence of two to 10 cases per 100,000 births.[94] Premature babies have even lower levels of the vitamin, so they are at a higher risk from this deficiency.

Bleeding in infants due to vitamin K deficiency can be severe, leading to hospitalizations, blood transfusions, brain damage, and death. Supplementation can prevent most cases of vitamin K deficiency bleeding in the newborn. Intramuscular administration is more effective in preventing late vitamin K deficiency bleeding than oral administration.[95][96]

USA

As a result of the occurrences of vitamin K deficiency bleeding, the Committee on Nutrition of the American Academy of Pediatrics has recommended 0.5 to 1.0 mg vitamin K1 be administered to all newborns shortly after birth.[96]

UK

In the UK, vitamin K is administered to newborns as either a single injection at birth or three orally administered doses given at birth and then over the baby's first month.

Controversy

Controversy arose in the early 1990s regarding this practice, when two studies suggested a relationship between parenteral administration of vitamin K and childhood cancer,[citation needed] however, poor methods and small sample sizes led to the discrediting of these studies, and a review of the evidence published in 2000 by Ross and Davies found no link between the two.[97]

Vitamin K and bone health

Both physiological and observational evidence indicate vitamin K plays a role in bone growth and the maintenance of bone density, but a large study attempting to delay the onset of osteoporosis by vitamin K supplementation proved ineffective.[98]

Vitamin K takes part in the post-translational modification as a cofactor in γ-carboxylation of vitamin K-dependant proteins (VKDPs). VKDPs have glutamate residues (Glu). Biophysical studies suggest that supplemental vitamin K promotes osteotrophic processes and slows osteoclastic processes via calcium bonding. Study of Atkins et al.[99] revealed phylloquinone, menatetrenone (MK-4) and menadione promote in vitro mineralization by human primary osteoblasts. Other studies have shown vitamin K antagonists (usually a class of anticoagulants) lead to early calcification of the epiphysis and epiphysial line in mice and other animals, causing seriously decreased bone growth, due to defects in osteocalcin and matrix Gla protein. Their primary function is to prevent overcalcification of the bone and cartilage. Vitamin K is important in the process of carboxylating glutamic acid (Glu) in these proteins to gamma-carboxyglutamic acid (Gla), which is necessary for their function.[100][101] Vitamin D is reported to regulate the OC transcription by osteoblast thereby showing that vitamin K and vitamin D work in tandem for the bone metabolism and development. Lian and his group discovered two nucleotide substitution regions they named "osteocalcin box" in the rat and human osteocalcin genes.[102] They found a region 600 nucleotides immediately upstream from the transcription start site that support a 10-fold stimulated transcription of the gene by 1,25-dihydroxy vitamin D.

Vitamin K1 and bone health

Data from the 1998 Nurses Health Study, an observational study, indicated an inverse relationship between dietary vitamin K1 and the risk of hip fracture. After being given 110 micrograms/day of vitamin K, women who consumed lettuce one or more times per day had a significantly lower risk of hip fracture than women who consumed lettuce one or fewer times per week. In addition to this, high intakes of vitamin D but low intakes of vitamin K were suggested to pose an increased risk of hip fracture.[101][103][failed verification] The Framingham Heart Study[104] is another study that showed a similar result. Subjects in the highest quartile of vitamin K1 intake (median K1 intake of 254 μg/ day) had a 35% lower risk of hip fracture than those in the lowest quartile. 254 μg/day is above the US Daily Reference Intake (DRI) of 90 μg/day for women and 120 μg/day for men. (See above)

In the face of this evidence, a large multicentre, randomized, placebo-controlled trial was performed to test the supplementation of vitamin K in postmenopausal women with osteopenia. Despite heavy doses of vitamin K1, no differences were found in bone density between the supplemented and placebo groups.[98]

Vitamin K2 (MK-4) and bone health

MK-4 has been shown in numerous studies to reduce fracture risk, and stop and reverse bone loss. In Japan, MK-4 in the dose of 45 mg daily is recognized as a treatment for osteoporosis[103][105] under the trade name Glakay.[106] MK-4 has been shown to decrease fractures up to 87%.[14] In the amount of 45 mg daily MK-4 has been approved by the Ministry of Health in Japan since 1995 for the prevention and treatment of osteoporosis.[15]

MK-4 (but not MK-7 or vitamin K1) prevented bone loss and/or fractures in the following circumstances:

Vitamin K2 (MK-7) and bone health

Menaquinone-7 (MK-7), which is abundant in fermented soybeans (natto), has been demonstrated to stimulate osteoblastic bone formation and to inhibit osteoclastic bone resorption.[107] In another study, use of MK-7 caused significant elevations of serum Y-carboxylated osteocalcin concentration, a biomarker of bone formation. MK-7 also completely inhibited a decrease in the calcium content of bone tissue by inhibiting the bone-resorbing factors parathyroid hormone and prostaglandin E2.[108] On 19 February 2011, HSA (Singapore) approved a health supplement that contains vitamin K2 (MK-7) and vitamin D3 for increasing bone mineral density.[109]

Vitamin K2 (MK-7) and coronary heart disease

A study by Gast et al. (2009),[72] reports "an inverse association between vitamin K(2) and risk of CHD with a Hazard Ratio (HR) of 0.91 [95% CI 0.85–1.00] per 10 μg/d vitamin K(2) intake. This association was mainly due to vitamin K(2) subtypes MK-7, MK-8 and MK-9. Vitamin K(1) intake was not significantly related to CHD. The authors conclude that "a high intake of menoquinones, especially MK-7, MK-8 and MK-9, could protect against CHD. However, more research is necessary to define optimal intake levels of vitamin K intake for the prevention of CHD."

Vitamin K and Alzheimer's disease

Research into the antioxidant properties of vitamin K indicates that the concentration of vitamin K is lower in the circulation of carriers of the APOE4 gene, and recent studies have shown its ability to inhibit nerve cell death due to oxidative stress. It has been hypothesized that vitamin K may reduce neuronal damage and that supplementation may hold benefits to treating Alzheimer's disease, although more research is necessary in this area.[110]

Vitamin K used topically

Vitamin K may be applied topically, typically as a 5% cream, to diminish postoperative bruising from cosmetic surgery and injections, to treat broken capillaries (spider veins), to treat rosacea, and to aid in the fading of hyperpigmentation and dark under-eye circles.[111][112]

Vitamin K and cancer

While researchers in Japan were studying the role of vitamin K2 as the menaquinone-4 (MK-4) form in the prevention of bone loss in females with liver disease, they discovered another possible effect. This two-year study that involved 21 women with viral liver cirrhosis found that women in the supplement group were 90% less likely to develop liver cancer.[113][114] A German study performed on men with prostate cancer found a significant inverse relationship between vitamin K2 consumption and advanced prostate cancer.[115]

In 2006, a clinical trial showed that K2 as the menaquinone-4 (MK-4) (called menatetrenone in the study) might be able to reduce recurrence of liver cancer after surgery. It should be noted that this was a small pilot study and other similar studies did not show much effect. MK-4 is now being tested along with other drugs to reduce liver cancer and has shown promising early results.[116]

Vitamin K and diabetes in the elderly

A research shows that total diabetes risk of individual who have highest circulating levels of vitamin K1 were 51% lower than those with the lowest levels. The researchers conclude that dietary phylloquinone intake is associated with reduced risk of type 2 diabetes.[117]

Vitamin K and non-Hodgkin lymphoma

A research shows that the risk of developing non-Hodgkin lymphoma was decreased by 45 percent for the study participants who had the highest vitamin K levels compared to participants with the lowest levels of the vitamin.[118]

Vitamin K as antidote for poisoning by 4-hydroxycoumarin drugs

Vitamin K is part of the suggested treatment regime for poisoning by rodenticide.[119]

Vitamin K antagonists are substances that reduce blood clotting by reducing the active form of vitamin K. They are used as rat poisons and as medications to prevent thrombosis. Examples include 4-hydroxycoumarins such as the pharmaceutical warfarin, and also anticoagulant-mechanism poisons such as bromadiolone, which are commonly found in rodenticides.[citation needed]

4-Hydroxycoumarin drugs possess anticoagulatory and rodenticidal properties because they inhibit recycling of vitamin K and thus cause simple deficiency of active vitamin K. This deficiency results in decreased vitamin K-dependent synthesis of some clotting factors by the liver. Death is usually a result of internal hemorrhage. Treatment for rodenticide poisoning usually consists of repeated intravenous doses of vitamin K, followed by doses in pill form for a period of at least two weeks, though possibly up to 2 months, after poisoning (this is necessary for the more potent 4-hydoxycoumarins used as rodenticides, which act by being fat-soluble and thus having a longer residence time in the body). If caught early, prognosis is good even when great amounts of the drug or poison are ingested, as these drugs are not true vitamin K antagonists, so the same amount of fresh vitamin K administered each day is sufficient for any dose of poison (although as noted, this must be continued for a longer time with more potent poisons). No matter how large the dose of these agents, they can do no more than prevent vitamin K from being recycled, and this metabolic problem may always be simply reversed by giving sufficient vitamin K (often 5 mg per day) to ensure that enough fresh vitamin K resides in the tissues to carry out its normal functions, even when efficient use of it by the body is prevented by the poison.

Vitamin K and brain sulfatides

A recent study has shown that rats who are fed excess amounts of vitamin K had greater amounts of brain sulfatide concentrations.[120] This study indicates that vitamin K has more uses than originally thought, thus furthering the importance of daily vitamin K intake. The same study showed that a diet with insufficient vitamin K levels decreased the brain sulfatide concentrations in rats at the (p < . 01) significance level. Another study involving rats has indicated that different species, strains and genders of rats required different amounts of vitamin K intake, depending on how much was stored in their livers.[121] This may indicate that different humans should have different needs for their vitamin K intake. A third study looked at the way rats and chicks are able to recycle parts of vitamin K. The study found that chicks are about 10% less efficient in recycling the vitamin K than their rat counterparts.[122] This evidences also helps to confirm that vitamin K levels are unique to each species, and the previous study shows that required vitamin K intake also varies within species.

History of discovery

In 1929, Danish scientist Henrik Dam investigated the role of cholesterol by feeding chickens a cholesterol-depleted diet.[123] After several weeks, the animals developed hemorrhages and started bleeding. These defects could not be restored by adding purified cholesterol to the diet. It appeared that—together with the cholesterol—a second compound had been extracted from the food, and this compound was called the coagulation vitamin. The new vitamin received the letter K because the initial discoveries were reported in a German journal, in which it was designated as Koagulationsvitamin. Edward Adelbert Doisy of Saint Louis University did much of the research that led to the discovery of the structure and chemical nature of vitamin K.[124] Dam and Doisy shared the 1943 Nobel Prize for medicine for their work on vitamin K (K1 and K2) published in 1939. Several laboratories synthesized the compound(s) in 1939.[125]

For several decades, the vitamin K-deficient chick model was the only method of quantifying vitamin K in various foods: the chicks were made vitamin K-deficient and subsequently fed with known amounts of vitamin K-containing food. The extent to which blood coagulation was restored by the diet was taken as a measure for its vitamin K content. Three groups of physicians independently found this: Biochemical Institute, University of Copenhagen (Dam and Johannes Glavind), University of Iowa Department of Pathology (Emory Warner, Kenneth Brinkhous, and Harry Pratt Smith), and the Mayo Clinic (Hugh Butt, Albert Snell, and Arnold Osterberg).[126]

The first published report of successful treatment with vitamin K of life-threatening hemorrhage in a jaundiced patient with prothrombin deficiency was made in 1938 by Smith, Warner, and Brinkhous.[127]

The precise function of vitamin K was not discovered until 1974, when three laboratories (Stenflo et al.,[128] Nelsestuen et al.,[129] and Magnusson et al.[130]) isolated the vitamin K-dependent coagulation factor prothrombin (Factor II) from cows that received a high dose of a vitamin K antagonist, warfarin. It was shown that, while warfarin-treated cows had a form of prothrombin that contained 10 glutamate amino acid residues near the amino terminus of this protein, the normal (untreated) cows contained 10 unusual residues that were chemically identified as gamma-carboxyglutamate, or Gla. The extra carboxyl group in Gla made clear that vitamin K plays a role in a carboxylation reaction during which Glu is converted into Gla.

The biochemistry of how vitamin K is used to convert Glu to Gla has been elucidated over the past thirty years in academic laboratories throughout the world.

References

  1. ^ "Vitamin K Overview". University of Maryland Medical Center.
  2. ^ a b Higdon (February 2008). "Vitamin K". Linus Pauling Institute, Oregon State University. Retrieved 12 April 2008.
  3. ^ Newman P., Shearer MJ; Newman, Paul (2008). "Metabolism and cell biology of vitamin K". Thrombosis and Haemostasis: 530–547. doi:10.1160/TH08-03-0147.
  4. ^ Davidson, RT (1998). "Conversion of Dietary Phylloquinone to Tissue Menaquinone-4 in Rats is Not Dependent on Gut Bacteria1". Journal of Nutrition. 128 (2): 220–223. PMID 9446847. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  5. ^ Ronden, JE (1998). "Intestinal flora is not an intermediate in the phylloquinone-menaquinone-4 conversion in the rat". Biochimica et Biophysica Acta (BBA) – General Subjects. 1379 (1): 69–75. doi:10.1016/S0304-4165(97)00089-5. PMID 9468334. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  6. ^ Thijssen, HHW (1994). "Vitamin K distribution in rat tissues: dietary phylloquinone is a source of tissue menaquinone-4". British Journal of Nutrition. 72 (3): 415–425. doi:10.1079/BJN19940043. PMID 7947656. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  7. ^ Will, BH (1992). "Comparative Metabolism and Requirement of Vitamin K in Chicks and Rats". Journal of Nutrition. 122 (12): 2354–2360. PMID 1453219. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  8. ^ Davidson, RT (1998). "Conversion of Dietary Phylloquinone to Tissue Menaquinone-4 in Rats is Not Dependent on Gut Bacteria". Journal of Nutrition. 128 (2): 220–223. PMID 9446847. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  9. ^ Ronden, JE (1998). "Intestinal flora is not an intermediate in the phylloquinone-menaquinone-4 conversion in the rat". Biochimica et Biophysica Acta (BBA) – General Subjects. 1379 (1): 69–75. doi:10.1016/S0304-4165(97)00089-5. PMID 9468334. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  10. ^ Al Rajabi, Ala (2011) The Enzymatic Conversion of Phylloquinone to Menaquinone-4. Ph.D. thesis, Tufts University, Friedman School of Nutrition Science and Policy.
  11. ^ Vermeer, C (2001). "Role of K vitamins in the regulation of tissue calcification". Journal of bone and mineral metabolism. 19 (4): 201–206. doi:10.1007/s007740170021. PMID 11448011. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  12. ^ Suttie, JW (1995). "The importance of menaquinones in human nutrition". Annual Review of Nutrition. 15: 399–417. doi:10.1146/annurev.nu.15.070195.002151. PMID 8527227.
  13. ^ Weber, P (2001). "Vitamin K and bone health". Nutrition. 17 (10): 880–887. doi:10.1016/S0899-9007(01)00709-2. PMID 11684396.
  14. ^ a b Sato, Y (2005). "Menatetrenone and vitamin D2 with calcium supplements prevent nonvertebral fracture in elderly women with Alzheimer's disease". Bone. 36 (1): 61–8. doi:10.1016/j.bone.2004.09.018. PMID 15664003. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  15. ^ a b c d Iwamoto, I (1999). "A longitudinal study of the effect of vitamin K2 on bone mineral density in postmenopausal women a comparative study with vitamin D3 and estrogen-progestin therapy". Maturitas. 31 (2): 161–164. doi:10.1016/S0378-5122(98)00114-5. PMID 10227010. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  16. ^ a b Inoue, T (2001). "Inverse correlation between the changes of lumbar bone mineral density and serum undercarboxylated osteocalcin after vitamin K2 (menatetrenone) treatment in children treated with glucocorticoid and alfacalcidol". Endocrine Journal. 48 (1): 11–18. doi:10.1507/endocrj.48.11. PMID 11403096. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  17. ^ a b Sasaki, N, Kusano E, Takahashi H, Ando Y, Yano K, Tsuda E, Asano Y (2005). "Vitamin K2 inhibits glucocorticoid-induced bone loss partly by preventing the reduction of osteoprotegerin (OPG)". Journal of bone and mineral metabolism. 23 (1): 41–47. doi:10.1007/s00774-004-0539-6. PMID 15616893. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: multiple names: authors list (link)
  18. ^ a b Yonemura, K (2004). "Protective effect of vitamins K2 and D3 on prednisolone-induced loss of bone mineral density in the lumbar spine". American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. 43 (1): 53–60. doi:10.1053/j.ajkd.2003.09.013. PMID 14712427. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  19. ^ a b Yonemura, K (2000). "Short-term effect of vitamin K administration on prednisolone-induced loss of bone mineral density in patients with chronic glomerulonephritis". Calcified Tissue International. 66 (2): 123–128. doi:10.1007/PL00005832. PMID 10652960. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  20. ^ a b Iketani, T (2003). "Effect of menatetrenone (vitamin K2) treatment on bone loss in patients with anorexia nervosa". Psychiatry Research. 117 (3): 259–269. doi:10.1016/S0165-1781(03)00024-6. PMID 12686368. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  21. ^ a b Shiomi, S (2002). "Vitamin K2 (menatetrenone) for bone loss in patients with cirrhosis of the liver". The American Journal of Gastroenterology. 97 (4): 978–981. doi:10.1111/j.1572-0241.2002.05618.x. PMID 12003435. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  22. ^ a b Cockayne, S (2006). "Vitamin K and the Prevention of Fractures: Systematic Review and Meta-analysis of Randomized Controlled Trials". Archives of Internal Medicine. 166 (12): 1256–1261. doi:10.1001/archinte.166.12.1256. PMID 16801507. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  23. ^ a b Iwamoto, J (2000). "Effect of combined administration of vitamin D3 and vitamin K2 on bone mineral density of the lumbar spine in postmenopausal women with osteoporosis". Journal of Orthopaedic Science. 5 (6): 546–551. doi:10.1007/s007760070003. PMID 11180916. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  24. ^ a b Purwosunu, Y (2006). "Vitamin K2 treatment for postmenopausal osteoporosis in Indonesia". The journal of obstetrics and gynaecology research. 32 (2): 230–234. doi:10.1111/j.1447-0756.2006.00386.x. PMID 16594930. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  25. ^ a b Shiraki, M (2000). "Vitamin K2 (Menatetrenone) Effectively Prevents Fractures and Sustains Lumbar Bone Mineral Density in Osteoporosis". Journal of Bone and Mineral Research. 15 (3): 515–522. doi:10.1359/jbmr.2000.15.3.515. PMID 10750566. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  26. ^ a b c Ushiroyama, T (2002). "Effect of continuous combined therapy with vitamin K2 and vitamin D3 on bone mineral density and coagulofibrinolysis function in postmenopausal women". Maturitas. 41 (3): 211–221. doi:10.1016/S0378-5122(01)00275-4. PMID 11886767. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  27. ^ a b Sato, Y (1998). "Menatetrenone ameliorates osteopenia in disuse-affected limbs of vitamin D- and K-deficient stroke patients". Bone. 23 (3): 291–296. doi:10.1016/S8756-3282(98)00108-2. PMID 9737352. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  28. ^ a b Sato, Y (2005). "Menatetrenone and vitamin D2 with calcium supplements prevent nonvertebral fracture in elderly women with Alzheimer's disease". Bone. 36 (1): 61–68. doi:10.1016/j.bone.2004.09.018. PMID 15664003. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  29. ^ a b Sato, Y (2002). "Amelioration of osteoporosis by menatetrenone in elderly female Parkinson's disease patients with vitamin D deficiency". Bone. 31 (1): 114–118. doi:10.1016/S8756-3282(02)00783-4. PMID 12110423. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  30. ^ a b Nishiguchi, S (2001). "Randomized pilot trial of vitamin K2 for bone loss in patients with primary biliary cirrhosis". Journal of Hepatology. 35 (4): 543–545. doi:10.1016/S0168-8278(01)00133-7. PMID 11682046. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  31. ^ a b Somekawa, Y (1999). "Use of vitamin K2 (menatetrenone) and 1,25-dihydroxyvitamin D3 in the prevention of bone loss induced by leuprolide". The Journal of Clinical Endocrinology and Metabolism. 84 (8): 2700–2704. doi:10.1210/jc.84.8.2700. PMID 10443663. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  32. ^ McGee, W (1 February 2007). "Vitamin K". MedlinePlus. Retrieved 2 April 2009.
  33. ^ Furie B, Bouchard BA, Furie BC (15 March 1999). "Vitamin K-dependent biosynthesis of gamma-carboxyglutamic acid". Blood. 93 (6): 1798–808. PMID 10068650.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  34. ^ Mann KG (1999). "Biochemistry and physiology of blood coagulation". Thromb. Haemost. 82 (2): 165–74. PMID 10605701.
  35. ^ Price PA (1988). "Role of vitamin-K-dependent proteins in bone metabolism". Annu. Rev. Nutr. 8: 565–83. doi:10.1146/annurev.nu.08.070188.003025. PMID 3060178.
  36. ^ Coutu DL, Wu JH, Monette A, Rivard GE, Blostein MD, Galipeau J (2008). "Periostin, a member of a novel family of vitamin K-dependent proteins, is expressed by mesenchymal stromal cells". J. Biol. Chem. 283 (26): 17991–18001. doi:10.1074/jbc.M708029200. PMID 18450759.{{cite journal}}: CS1 maint: multiple names: authors list (link) CS1 maint: unflagged free DOI (link)
  37. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 18836183, please use {{cite journal}} with |pmid=18836183 instead.
  38. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 19893032, please use {{cite journal}} with |pmid=19893032 instead.
  39. ^ Hafizi S, Dahlbäck B (2006). "Gas6 and protein S. Vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily". FEBS J. 273 (23): 5231–44. doi:10.1111/j.1742-4658.2006.05529.x. PMID 17064312.
  40. ^ Kulman JD, Harris JE, Xie L, Davie EW (2007). "Proline-rich Gla protein 2 is a cell-surface vitamin K-dependent protein that binds to the transcriptional coactivator Yes-associated protein". Proc. Natl. Acad. Sci. U.S.A. 104 (21): 8767–72. doi:10.1073/pnas.0703195104. PMC 1885577. PMID 17502622.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  41. ^ "Vitamin K". National Institute of Health. Retrieved 26 May 2009.
  42. ^ Conly, J (1994). "Reduction of vitamin K2 concentrations in human liver associated with the use of broad spectrum antimicrobials". Clinical and investigative medicine. Médecine clinique et experimentale. 17 (6): 531–539. PMID 7895417. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  43. ^ Ferland G, Sadowski JA, O'Brien ME (1993). "Dietary induced subclinical vitamin K deficiency in normal human subjects". The Journal of Clinical Investigation. 91 (4): 1761–8. doi:10.1172/JCI116386. PMC 288156. PMID 8473516.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  44. ^ Holden, RM (April 2010). "Vitamins K and D status in stages 3–5 chronic kidney disease". Clinical journal of the American Society of Nephrology : CJASN. 5 (4): 590–7. doi:10.2215/CJN.06420909. PMC 2849681. PMID 20167683. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  45. ^ Hodges SJ, Pilkington MJ, Shearer MJ, Bitensky L, Chayen J (1990). "Age-related changes in the circulating levels of congeners of vitamin K2, menaquinone-7 and menaquinone-8". Clinical Science. 78 (1): 63–6. PMID 2153497.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  46. ^ Groenen-van Dooren MM, Ronden JE, Soute BA, Vermeer C (1995). "Bioavailability of phylloquinone and menaquinones after oral and colorectal administration in vitamin K-deficient rats". Biochem. Pharmacol. 50 (6): 797–801. doi:10.1016/0006-2952(95)00202-B. PMID 7575640.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  47. ^ Komai M, Shirakawa H (2007). "[Vitamin K metabolism. Menaquinone-4 (MK-4) formation from ingested VK analogues and its potent relation to bone function]". Clin Calcium (in Japanese). 17 (11): 1663–72. PMID 17982185.
  48. ^ Geleijnse JM; Vermeer C; Grobbee DE; Schurgers, LJ; Knapen, MH; Van Der Meer, IM; Hofman, A; Witteman, JC (2004). "Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study" (PDF). J. Nutr. 134 (11): 3100–5. PMID 15514282.
  49. ^ Beulens JW, Bots ML, Atsma F, Bartelink ML, Prokop M, Geleijnse JM, Witteman JC, Grobbee DE, van der Schouw YT (2009). "High dietary menaquinone intake is associated with reduced coronary calcification". Atherosclerosis. 203 (2): 489–93. doi:10.1016/j.atherosclerosis.2008.07.010. PMID 18722618.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  50. ^ Nimptsch K, Rohrmann S, Kaaks R, Linseisen J (2010). "Dietary vitamin K intake in relation to cancer incidence and mortality: results from the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC-Heidelberg)" (PDF). Am. J. Clin. Nutr. 91 (5): 1348–58. doi:10.3945/ajcn.2009.28691. PMID 20335553.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  51. ^ Spronk, HMH (2003). "Tissue-Specific Utilization of Menaquinone-4 Results in the Prevention of Arterial Calcification in Warfarin-Treated Rats". Journal of vascular research. 40 (6): 531–537. doi:10.1159/000075344. PMID 14654717. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  52. ^ Binkley NC, Krueger DC, Kawahara TN, angelke JA, Chappell RJ, Suttie JW (2002). "A high phylloquinone intake is required to achieve maximal osteocalcin gamma-carboxylation" (PDF). Am. J. Clin. Nutr. 76 (5): 1055–60. PMID 12399278.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  53. ^ Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E (2004). "The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy". Chest. 126 (3 Suppl): 204S–233S. doi:10.1378/chest.126.3_suppl.204S. PMID 15383473.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  54. ^ Crowther MA; Douketis JD; Schnurr T; Steidl, L; Mera, V; Ultori, C; Venco, A; Ageno, W (2002). "Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial". Ann. Intern. Med. 137 (4): 251–4. doi:10.7326/0003-4819-137-4-200208200-00009. PMID 12186515.
  55. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 17138823, please use {{cite journal}} with |pmid=17138823 instead.
  56. ^ Attention: This template ({{cite doi}}) is deprecated. To cite the publication identified by doi:10.1159/000075344, please use {{cite journal}} (if it was published in a bona fide academic journal, otherwise {{cite report}} with |doi=10.1159/000075344 instead.
  57. ^ Pradaxa Drug Interactions. Pradaxapro.com (19 March 2012). Retrieved on 21 April 2013.
  58. ^ Bauersachs, R (2010). "Oral Rivaroxaban for Symptomatic Venous Thromboembolism". New England Journal of Medicine. 363 (26): 2499–2510. doi:10.1056/NEJMoa1007903. PMID 21128814. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  59. ^ a b Rhéaume-Bleue, p. 42
  60. ^ Important information to know when you are taking: Warfarin (Coumadin) and Vitamin K. National Institutes of Health Clinical Center. cc.nih.gov
  61. ^ Nutrition Facts and Information for Parsley, raw. Nutritiondata.com. Retrieved on 21 April 2013.
  62. ^ Nutrition facts, calories in food, labels, nutritional information and analysis. Nutritiondata.com (13 February 2008). Retrieved on 21 April 2013.
  63. ^ Vitamin K. Vivo.colostate.edu (2 July 1999). Retrieved on 21 April 2013.
  64. ^ food sources for vitamin K2. Livestrong.com. Retrieved on 21 April 2013.
  65. ^ Elder SJ, Haytowitz DB, Howe J, Peterson JW, Booth SL (2006). "Vitamin k contents of meat, dairy, and fast food in the U.S. Diet". J. Agric. Food Chem. 54 (2): 463–7. doi:10.1021/jf052400h. PMID 16417305.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  66. ^ Tsukamoto Y, Ichise H, Kakuda H, Yamaguchi M (2000). "Intake of fermented soybean (natto) increases circulating vitamin K2 (menaquinone-7) and gamma-carboxylated osteocalcin concentration in normal individuals". J. Bone Miner. Metab. 18 (4): 216–22. doi:10.1007/s007740070023. PMID 10874601.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  67. ^ "On the Trail of the Elusive X-Factor: Vitamin K2 Revealed".[verification needed]
  68. ^ "Micronutrient Data Centre: Vitamin K".
  69. ^ Ikeda; Iki, M; Morita, A; Kajita, E; Kagamimori, S; Kagawa, Y; Yoneshima, H (2006). "Intake of fermented soybeans, natto, is associated with reduced bone loss in postmenopausal women: Japanese Population-Based Osteoporosis (JPOS) Study". The Journal of nutrition. 136 (5): 1323–8. PMID 16614424.
  70. ^ Katsuyama; Ideguchi, S; Fukunaga, M; Saijoh, K; Sunami, S (2002). "Usual dietary intake of fermented soybeans (Natto) is associated with bone mineral density in premenopausal women". Journal of nutritional science and vitaminology. 48 (3): 207–15. doi:10.3177/jnsv.48.207. PMID 12350079.
  71. ^ Sano; Fujita, H; Morita, I; Uematsu, H; Murota, S (1999). "Vitamin K2 (menatetrenone) induces iNOS in bovine vascular smooth muscle cells: no relationship between nitric oxide production and gamma-carboxylation". Journal of nutritional science and vitaminology. 45 (6): 711–23. doi:10.3177/jnsv.45.711. PMID 10737225.
  72. ^ a b Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 19179058, please use {{cite journal}} with |pmid=19179058 instead.
  73. ^ Geleijnse; Vermeer, C; Grobbee, DE; Schurgers, LJ; Knapen, MH; van der Meer, IM; Hofman, A; Witteman, JC (2004). "Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: The Rotterdam Study". The Journal of nutrition. 134 (11): 3100–5. PMID 15514282.
  74. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 16200467, please use {{cite journal}} with |pmid=16200467 instead.
  75. ^ Asakura, H (2001). "Vitamin K administration to elderly patients with osteoporosis induces no hemostatic activation, even in those with suspected vitamin K deficiency". Osteoporosis International. 12 (12): 996–1000. doi:10.1007/s001980170007. PMID 11846334. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  76. ^ Ronden, JE (1997). "Modulation of arterial thrombosis tendency in rats by vitamin K and its side chains". Atherosclerosis. 132 (1): 61–67. doi:10.1016/S0021-9150(97)00087-7. PMID 9247360. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  77. ^ Oldenburg J, Bevans CG, Müller CR, Watzka M (2006). "Vitamin K epoxide reductase complex subunit 1 (VKORC1): the key protein of the vitamin K cycle". Antioxid. Redox Signal. 8 (3–4): 347–53. doi:10.1089/ars.2006.8.347. PMID 16677080.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  78. ^ Suttie JW (1985). "Vitamin K-dependent carboxylase". Annu. Rev. Biochem. 54: 459–77. doi:10.1146/annurev.bi.54.070185.002331. PMID 3896125.
  79. ^ Presnell SR, Stafford DW (2002). "The vitamin K-dependent carboxylase". Thromb. Haemost. 87 (6): 937–46. PMID 12083499.
  80. ^ Stafford DW (2005). "The vitamin K cycle". J. Thromb. Haemost. 3 (8): 1873–8. doi:10.1111/j.1538-7836.2005.01419.x. PMID 16102054.
  81. ^ Rhéaume-Bleue, p. 79.
  82. ^ Whitlon DS, Sadowski JA, Suttie JW (1978). "Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition". Biochemistry. 17 (8): 1371–7. doi:10.1021/bi00601a003. PMID 646989.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  83. ^ Terlau H, Olivera BM (2004). "Conus venoms: a rich source of novel ion channel-targeted peptides". Physiol. Rev. 84 (1): 41–68. doi:10.1152/physrev.00020.2003. PMID 14715910.
  84. ^ Buczek O, Bulaj G, Olivera BM (2005). "Conotoxins and the posttranslational modification of secreted gene products". Cell. Mol. Life Sci. 62 (24): 3067–79. doi:10.1007/s00018-005-5283-0. PMID 16314929.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  85. ^ Prothrombin Time. webmd.com
  86. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 22280352, please use {{cite journal}} with |pmid=22280352 instead.
  87. ^ Thane CW; Bates CJ; Shearer MJ; Unadkat, N.; Harrington, D.J.; Paul, A.A.; Prentice, A.; Bolton-Smith, C. (2002). "Plasma phylloquinone (vitamin K1) concentration and its relationship to intake in a national sample of British elderly people". Br. J. Nutr. 87 (6): 615–22. doi:10.1079/BJNBJN2002582. PMID 12067432.
  88. ^ McKeown NM; Jacques PF; Gundberg CM; Peterson, JW; Tucker, KL; Kiel, DP; Wilson, PW; Booth, SL (2002). "Dietary and nondietary determinants of vitamin K biochemical measures in men and women" (PDF). J. Nutr. 132 (6): 1329–34. PMID 12042454.
  89. ^ Yamano M, Yamanaka Y, Yasunaga K, Uchida K (1989). "Effect of vitamin K deficiency on urinary gamma-carboxyglutamic acid excretion in rats". Nippon Ketsueki Gakkai Zasshi. 52 (6): 1078–86. PMID 2588957.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  90. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 21944271, please use {{cite journal}} with |pmid=21944271 instead.
  91. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 21860562, please use {{cite journal}} with |pmid=21860562 instead.
  92. ^ Bentley R, Meganathan R (1982). "Biosynthesis of vitamin K (menaquinone) in bacteria" (PDF). Microbiol. Rev. 46 (3): 241–80. PMC 281544. PMID 6127606.
  93. ^ Haddock BA, Jones CW (1977). "Bacterial respiration" (PDF). Bacteriol Rev. 41 (1): 47–99. PMC 413996. PMID 140652.
  94. ^ Shearer MJ (1995). "Vitamin K". Lancet. 345 (8944): 229–34. doi:10.1016/S0140-6736(95)90227-9. PMID 7823718.
  95. ^ Wintrobe's Clinical Hematology, 11th Edition. J.P. Greer, Foerster J., Lukens, J.N., Rodgers, G.M., Paraskevas, F., and Glader, B., editor. Philadelphia, PA, USA: Lippincott Williams and Wilkens.
  96. ^ a b American Academy of Pediatrics Committee on Fetus and Newborn (2003). "Controversies concerning vitamin K and the newborn. American Academy of Pediatrics Committee on Fetus and Newborn" (PDF). Pediatrics. 112 (1 Pt 1): 191–2. doi:10.1542/peds.112.1.191. PMID 12837888.
  97. ^ McMillan DD (1997). "Routine administration of vitamin K to newborns". Paediatr Child Health. 2 (6): 429–31.
  98. ^ a b Cheung AM, Tile L, Lee Y, Tomlinson G, Hawker G, Scher J, Hu H, Vieth R, Thompson L, Jamal S, Josse R (2008). Torgerson (ed.). "Vitamin K Supplementation in Postmenopausal Women with Osteopenia (ECKO Trial): A Randomized Controlled Trial". PLoS Med. 5 (10): 1–12. doi:10.1371/journal.pmed.0050196. PMC 2566998. PMID 18922041.{{cite journal}}: CS1 maint: multiple names: authors list (link) CS1 maint: unflagged free DOI (link)
  99. ^ Gerald JA; Katie JW; Asiri R W; Bonewald, L. F.; Findlay, D. M. (2009). "Vitamin K promotes mineralization, osteoblast‐to‐osteocyte transition, and an anticatabolic phenotype by γ‐carboxylation‐dependent and independent mechanisms". Am J Physiol Cell Physiol. 297 (6): C1358–C1367. doi:10.1152/ajpcell.00216.2009. PMID 19675304.
  100. ^ Drenckhahn, D. & Kugler, P (2003), "Knochengewebe". In Benninhoff & D. Drenhahn, Anatomie Band 1:147. Munich, Germany: Urban & Fisher
  101. ^ a b Brown, Susan E. "Key vitamins for bone health — vitamins K1 and K2". womentowomen.com. Retrieved 11 August 2010.
  102. ^ Lian J, Stewart C, Puchacz E, Mackowiak S, Shalhoub V, Collart D, Zambetti G & Stein G (1989). "Structure of the rat osteocalcin gene and regulation of vitamin D-dependent expression". Proc. Natl. Acad. Sci. USA. 86 (4): 1143–1147. doi:10.1073/pnas.86.4.1143. PMC 286642. PMID 2784002.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  103. ^ a b Kanai, T; Takagi, T.; Masuhiro, K.; Nakamura, M.; Iwata, M.; Saji, F. (1997). "Serum vitamin K level and bone mineral density in post-menopausal women". International Journal of Gynecology & Obstetrics. 56: 25. doi:10.1016/S0020-7292(96)02790-7.
  104. ^ Booth SL, Tucker KL, Chen H, Hannan MT, Gagnon DR, Cupples LA, Wilson PW, Ordovas J, Schaefer EJ, Dawson-Hughes B, Kiel DP (2000). "Dietary vitamin K intakes are associated with hip fracture but not with bone mineral density in elderly men and women". Am J Clin Nutr. 71 (5): 1201–1208. PMID 10799384.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  105. ^ Feskanich, Diane; Weber, P; Willett, W; Rockett, H; Booth, S; Colditz, G (1999). "Vitamin K intake and hip fractures in women: a prospective study" (PDF). American Journal of Clinical Nutrition. 69 (1): 74–9. PMID 9925126.
  106. ^ Glakay prescribing information. Eisai Co., Ltd..
  107. ^ Yamaguchi M (2006). "Regulatory mechanism of food factors in bone metabolism and prevention of osteoporosis". Yakugaku Zasshi. 126 (11): 1117–37. doi:10.1248/yakushi.126.1117. PMID 17077614.
  108. ^ Tsukamoto Y (2004). "Studies on action of menaquinone-7 in regulation of bone metabolism and its preventive role of osteoporosis". BioFactors. 22 (1–4): 5–19. doi:10.1002/biof.5520220102. PMID 15630245.
  109. ^ Ref. no. HPRG (HSU) 2011-02-0016. Iabpi.com (16 March 2011). Retrieved on 21 April 2013.
  110. ^ Allison AC (2001). "The possible role of vitamin K deficiency in the pathogenesis of Alzheimer's disease and in augmenting brain damage associated with cardiovascular disease". Medical hypotheses. 57 (2): 151–5. doi:10.1054/mehy.2001.1307. PMID 11461163.
  111. ^ Cohen, JL (November 2009). "The role of topical vitamin K oxide gel in the resolution of postprocedural purpura". Journal of drugs in dermatology : JDD. 8 (11): 1020–4. PMID 19894369. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  112. ^ Leu, S (September 2010). "Accelerated resolution of laser-induced bruising with topical 20% arnica: a rater-blinded randomized controlled trial". The British journal of dermatology. 163 (3): 557–63. doi:10.1111/j.1365-2133.2010.09813.x. PMID 20412090. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  113. ^ "Vitamin K Found to Protect Against Liver Cancer". utraingredients.com (21 July 2004)
  114. ^ Saxena SP, Israels ED, Israels LG (2001). "Novel vitamin K-dependent pathways regulating cell survival". Apoptosis. 6 (1–2): 57–68. doi:10.1023/A:1009624111275. PMID 11321042.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  115. ^ Nimptsch K, Rohrmann S, Linseisen J (2008). "Dietary intake of vitamin K and risk of prostate cancer in the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition. (EPIC-Heidelberg)" (PDF). Am. J. Clin. Nutr. 87 (4): 985–92. PMID 18400723.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  116. ^ American Cancer Society: Vitamin K. Cancer.org. Retrieved on 21 April 2013.
  117. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 23034962, please use {{cite journal}} with |pmid=23034962 instead.
  118. ^ Cerhan J. 101st Annual Meeting of the American Association for Cancer Research (AACR). 2012
  119. ^ Lung D. Tarabar A (ed.). "Rodenticide Toxicity Treatment & Management". Retrieved March 2014. {{cite web}}: Check date values in: |accessdate= (help)
  120. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 8914944, please use {{cite journal}} with |pmid=8914944 instead.
  121. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 7310534, please use {{cite journal}} with |pmid=7310534 instead.
  122. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 1453219, please use {{cite journal}} with |pmid=1453219 instead.
  123. ^ Cite error: The named reference Dam was invoked but never defined (see the help page).
  124. ^ MacCorquodale, D. W. (1939). "On the constitution of Vitamin K1". Journal of the American Chemical Society. 61 (7): 1928–1929. doi:10.1021/ja01876a510. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  125. ^ Fieser, L. F. (1939). "Synthesis of Vitamin K1". Journal of the American Chemical Society. 61 (12): 3467–3475. doi:10.1021/ja01267a072.
  126. ^ Dam, Henrik (12 December 1946). The discovery of vitamin K, its biological functions and therapeutical application. Nobel Prize lecture
  127. ^ Warner, E. D. (1938). "Bleeding Tendency of Obstructive Jaundice". Proceedings of the Society of Experimental Biology and Medicine. 37: 628. doi:10.3181/00379727-37-9668P. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  128. ^ Stenflo J, Fernlund P, Egan W, Roepstorff P (1974). "Vitamin K Dependent Modifications of Glutamic Acid Residues in Prothrombin". Proc. Natl. Acad. Sci. U.S.A. 71 (7): 2730–3. doi:10.1073/pnas.71.7.2730. PMC 388542. PMID 4528109.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  129. ^ Nelsestuen GL, Zytkovicz TH, Howard JB (1974). "The mode of action of vitamin K. Identification of gamma-carboxyglutamic acid as a component of prothrombin" (PDF). J. Biol. Chem. 249 (19): 6347–50. PMID 4214105.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  130. ^ Magnusson S, Sottrup-Jensen L, Petersen TE, Morris HR, Dell A (1974). "Primary structure of the vitamin K-dependent part of prothrombin". FEBS Lett. 44 (2): 189–93. doi:10.1016/0014-5793(74)80723-4. PMID 4472513.{{cite journal}}: CS1 maint: multiple names: authors list (link)

Bibliography

  • Rhéaume-Bleue, Kate (2012). Vitamin K2 and the Calcium Paradox. John Wiley & Sons, Canada. ISBN 1118065727.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Vitamin_K&oldid=604013262"